Cambridge, UK-based Exonate has dose the first patient with its lead compound – EXN 407 – in a Phase Ib/II clinical trial investigating the drug in volunteers with centre-involved diabetic macular oedema (CI-DMO).
CAMBRIDGE, United Kingdom, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Exonate, an mRNA therapy company focused on retinal diseases, today announced that in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the first patient has been dosed with Exonate's lead compound, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema (CI-DMO). The original agreement with Janssen was facilitated by Johnson & Johnson Innovation.
Exonate, an mRNA therapy company focused on retinal diseases, announced that in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the first patient has been dosed with Exonate’s lead compound, EXN 407, in a phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema (CI-DMO). The original agreement with Janssen was facilitated by Johnson & Johnson Innovation.
Market Place
Share
Share
